Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712748 | 1.00 | PIK3CA (0.47) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL24478649 | 0.89 | TP53 (0.46) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL27101023 | 0.88 | PIK3CA (0.48) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL26676845 | 0.86 | GPR119 (0.46) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL26838507 | 0.85 | OPRM1 (0.44) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL26671826 | 0.85 | PIK3CA (0.41) | PIK3CAMTORPRKDC | |
| SCHEMBL24478453 | 0.84 | PIK3CA (0.46) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL24478093 | 0.84 | TP53 (0.41) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL26671857 | 0.83 | GPR119 (0.49) | PIK3CAMTORPRKDCGPR119OPRM1 | |
| SCHEMBL24478472 | 0.83 | PIK3CA (0.43) | PIK3CAMTORPRKDCGPR119OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| CN-116615199-A | Heterocyclic compounds as diacylglycerol kinase inhibitors and uses thereof | 株式会社LG化学 | 2023-08-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067645-A1 | HETEROCYCLIC COMPOUND AS DIACYLGLYCEROL KINASE INHIBITOR AND USE THEREOF | DGKA, DGKB, DGKK | PIK3CA 61/4885MTOR 101/4885PRKDC 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.